Poster Viewing Sessions
More information will follow.
Four poster viewing sessions are organized during the 32nd Annual Meeting.
More information about the schedule will follow soon.
Thursday, 21 November 2024
| 12:30 - 13:30 | Poster Viewing Session I | |
| 15:45 - 16:45 | Poster viewing II |
Friday, 22 November 2024
| 10:00 - 10:30 | Poster Viewing Session III | |
| 13:00 - 14:00 | Poster viewing IV |
During those sessions, our Young Investigators, ECF Fellows and Investigators will present their posters to the jury onsite. E-posters will be also available for consultation on the ECF website.
The winners of the 3 Young Investigators Awards (one Award per category) will be announced on Friday, 22 November 2024 from 17:20 - 17:30.
The winners will also present their posters during the Young Investigators Awards presentations which will be held on Saturday, 23 November 2024 from 10:30 - 11:00.
| Hour Location |
Title | Location |
|---|---|---|
|
12:30 - 13:30 |
Poster Viewing Session I: Category: TREATMENT + INVESTIGATIONS Prof. Dr Per Soelberg Sørensen Letizia Leocani Prof. Dr Krzysztof Selmaj |
|
| -- |
ID 31: Volumetric MRI Measurements as Predictors for Cognition in Multiple Sclerosis Deborah Erhart |
|
| -- |
ID 33: High-dose vitamin D reduces disease activity in early multiple sclerosis Manon Rival |
|
| -- |
ID 38: Transcranial direct current stimulation and wheel running in cuprizon demyelination Ms Elena Rossi |
|
| -- |
ID 40: Telerehabilitation for Cognitive Deficits in MS: A Randomised Controlled Trial Angela Boschetti |
|
| -- |
ID 43: Improving Digital Self-Monitoring of Cognition in People with Multiple Sclerosis Mr Michelangelo Dini |
|
| -- |
ID 48: Neurophysiological markers of cognitive processing in MS: an EEG study during SDMT Marta Tacchini |
|
| -- |
ID 65: Exercise programs for fatigue and motor deficits in people with multiple sclerosis Anna Boi |
|
| -- |
ID 69: Brain characteristics in patients with MOGAD by 7.0 T MRI Zhihui Qi |
|
| -- |
ID 73: Cortical microstructural MRI damage in MOGAD Dr Valentina Camera |
|
| -- |
ID 77: Failed, Interrupted, or Inconclusive Trials in Multiple Sclerosis: 2020-2024 Update Sara Samadzadeh |
|
| -- |
ID 78: Impact of multiple sclerosis treatments on brain remyelination Vitória Pimentel |
|
| -- |
ID 79: Real-world Disease-modifying Therapy Use in Multiple Sclerosis Patients Aged 55+ Mina Stanikic |
|
| -- |
ID 91: Quantitative Imaging Markers to Characterize Remyelination in a Mouse Model of MS Lina Anderhalten |
|
| -- |
-- |
|
| -- |
ID 16: CLadribine tablets level of respOnse preDIctors in cliNical prActice (CLODINA) Spyros Deftereos |
|
| -- |
ID 41: Efficacy and Safety of Tolebrutinib Vs Teriflunomide in RMS: Phase 3 GEMINI Trials Maria Pia Sormani |
|
| -- |
ID 44: Greater risk of post-partum MRI activity with SC vs IV Natalizumab EID in pregnancy Vito AG Ricigliano |
|
| -- |
ID 49: Efficacy and Safety of Natalizumab Extended vs. Standard Interval Dosing in RRMS Abdulkadir Tunç |
|
| -- |
ID 50: LONG TERM MANAGEMENT FOR RELAPSING MS PATIENTS IN FRANCE: A VIGNETTE STUDY Patrick Vermersch |
|
| -- |
ID 56: Wearing-Off Phenomenon and Outcomes in Ocrelizumab-Treated MS Patients Meral Seferoğlu |
|
| -- |
ID 61: Phase 2 Safety and Efficacy of Frexalimab in Relapsing MS: 18-Month Results Patrick Vermersch |
|
| -- |
ID 63: Exploratory MRI and Plasma NfL: Week 48 Phase 2 Data of Frexalimab in Relapsing MS Patrick Vermersch |
|
| -- |
ID 64: Phase 3 Studies of Frexalimab in MS: Design of FREXALT and FREVIVA Trials Patrick Vermersch |
|
| -- |
ID 67: Efficacy and Safety of Tolebrutinib in Non-Relapsing SPMS: Phase 3 HERCULES Results Patrick Vermersch |
|
| -- |
ID 81: Evoked potentials predict disability improvement after rehabilitation in PMS Alessandro Gradassi |
|
| -- |
ID 99: A new assay for detection of anti-JCV Abs for risk stratification of PML Maja Natek |
|
|
15:45 - 16:45 |
Poster Viewing Session II: Category: BASIC STUDIES Hans-Peter Hartung Dr. Kazuo Fujihara Hans Lassmann |
|
| -- |
ID 5: Psychosocial adjustment in MS compared to ALS and Huntington's disease Luisa Theresa Balz |
|
| -- |
ID 10: LKB1 Deficiency in Astrocytes Impairs Pantothenate Kinase and Promotes Ferroptosis Rebecca Alemani |
|
| -- |
ID 15: Formyl peptide as a potential biomarker for neurodegeneration in multiple sclerosis Zichun Xiao |
|
| -- |
ID 29: Impact of tDCS treatment in chronic Experimental Autoimmune Encephalomyelitis Dr Silvia Marenna |
|
| -- |
ID 30: 10 Hz tACS enhances myelin repair and spatial memory after cuprizone toxicity Thomas Scheinok |
|
| -- |
ID 36: Single-cell RNA-seq transcriptomics reveal shared characteristics of three diseases Haonan Guan |
|
| -- |
ID 37: Aberrant erythropoiesis leads to inflammatory anemia in multiple sclerosis Yu-Jing Li |
|
| -- |
ID 54: Human dental pulp stem cells reduce neuroinflammation in multiple sclerosis mice Yingying Chang |
|
| -- |
ID 57: CD163+ macrophages in the MS spinal cord associate with aberrant iron distribution Andrew Lockhart |
|
| -- |
ID 59: Decline of neuronal PD-L1 augments CD8+ T cell-mediated neuroinflammation in aging Nuo Cheng |
|
| -- |
ID 62: Diffuse vascular pathology and blood-brain barrier disruption in the MS spinal cord Marco Pisa |
|
| -- |
ID 66: Neuronal dysferlin expression in MS relates to aging and disease severity Marco Pisa |
|
| -- |
-- |
|
| -- |
ID 18: The tripartite protective role of Nurr1 in progressive MS spinal cord Dr Jonathan Pansieri |
|
| -- |
ID 20: D1-dopamine receptor modulates macrophages-induced Th17-immune response in MS Dr Mikhail Melnikov |
|
| -- |
ID 42: Remibrutinib Exposure in CSF: Insights from a Study in Healthy Subjects Bernd Kieseier |
|
| -- |
ID 52: Phenotypic changes of an IL1Bhigh monocyte cluster during anti-CD20 therapy Zsolt Illes |
|
| -- |
ID 92: Remyelinating potential of Transcorneal Electric Stimulation in the cuprizone model Dr Valerio Castoldi |
|
|
15:45 - 16:45 |
Poster Viewing Session II: Category: CLINICAL + EPIDEMIOLOGY Gilles Edan Prof. Dr Maria Trojano Prof. Dr Oscar Fernández |
|
| -- |
ID 4: The concerning trend of increasing burden of multiple sclerosis in Mexico Patricia Orozco |
|
| -- |
ID 6: Functional Gastrointestinal Disorders in Multiple Sclerosis Patients Andreea Plesa |
|
| -- |
ID 12: Clinical Management of Non-Relapsing Secondary Progressive Multiple Sclerosis Kristina Smith |
|
| -- |
ID 23: Sex-related gap in the use of disease-modifying therapies in multiple sclerosis Antoine Gavoille |
|
| -- |
ID 24: Impact of therapeutic management during pregnancy on relapse risk in women with MS Antoine Gavoille |
|
| -- |
ID 39: Unravelling the Sleep-Cognition Link in Multiple Sclerosis: A Systematic Review Laura-Elena Cucu |
|
| -- |
ID 45: Hepatitis B Vaccine Immunogenicity in MS Patients before and after Anti-CD20 Réné Carvajal |
|
| -- |
ID 46: Pre-existing Measles & Varicella humoral immunity in MS after Anti-CD20 initiation Réné Carvajal |
|
| -- |
ID 51: Drug addiction as a risk factor for progression in MS in a Mexican cohort Hiled Melissa Hernandez |
|
| -- |
ID 86: The MS severity variant rs10191329 and cognitive function: a UK Biobank study Ioanna Zimianiti |
|
| -- |
-- |
|
| -- |
ID 83: Healthcare Access and Associated Factors in Brazilian Multiple Sclerosis Patients Dr. Alfredo Damasceno |
| Hour Location |
Title | Location |
|---|---|---|
|
10:00 - 10:30 |
Poster Viewing Session III: CLINICAL |
|
| -- |
ID 11: Longitudinal optic coherence tomography imaging shows hyperreflective foci in RRMS Jette Frederiksen |
|
| -- |
ID 53: Pain in NMOSD and MOGAD: Prevalence, Predictors, and Impact on Quality of Life Emine Koc |
|
| -- |
ID 71: COMPARISON OF OCRELIZUMAB CONCENTRATION AND AUTO ANTIBODIES BETWEEN TEST FACILITIES Birgit Jensen |
|
| -- |
ID 76: Interim results from the SATYSFACTION study, Patient Satisfaction with Tysabri SC Yves Martinet |
|
| -- |
ID 84: Long-Term Outcomes in Female Participants of the Ozanimod Open-Label Extension Eva Kubala Havrdova |
|
| -- |
ID 88: SDMT and Safety Outcomes at 1 Year in the ENLIGHTEN Study of Ozanimod in Early RMS Robert Naismith |
|
| -- |
ID 89: Long-term ozanimod safety in the DAYBREAK open-label extension trial Prof. Dr Krzysztof Selmaj |
|
| -- |
ID 93: Multiple Sclerosis and overlapping syndromes: MS PLUS Concept Meral Seferoğlu |
|
| -- |
ID 95: Defining Smo[u]ldering Associated Worsening (SAW) in MS: The SAW index study Prof Dr Jeremy Hobart |
|
| -- |
ID 96: SymptoMScreen questionnaire: a suitable outcome measure for MS clinical trials? Prof Dr Jeremy Hobart |
|
| -- |
ID 97: EDSS: confirming requirements, advancing interpretations, exposing novel insights Prof Dr Jeremy Hobart |
|
| -- |
ID 98: Ocrelizumab slows the rate of change of EDSS-measured progression in relapsing MS Prof Dr Jeremy Hobart |
|
|
13:00 - 14:00 |
Poster Viewing Session IV: Category: CLINICAL + EPIDEMIOLOGY Gilles Edan Prof. Dr Maria Trojano Prof. Dr Oscar Fernández |
|
| -- |
ID 3: Markers for Early Detection of Secondary Progressive Multiple Sclerosis Mafalda Delgado Soares |
|
| -- |
ID 7: Atypical MS Presentation: Focal Seizures and Pseudotumoral Lesion in a Complex Case Andreea Plesa |
|
| -- |
ID 9: Leptospira Meningoencephalitis in a Patient with MS Treated with Betaferon Andreea Plesa |
|
| -- |
ID 13: Cutaneous side effects to dimethyl fumarate therapy: a case series Teodora-Ioana Simon |
|
| -- |
ID 14: Type-I IFN signaling augments autoreactive T cells and aggregates NMOSD Tian-Xiang Zhang |
|
| -- |
ID 25: Premature thymic involution in autoimmune diseases: a radiographic analysis Xiaoyu Huang |
|
| -- |
ID 32: Brain Lesion Characteristics in Chinese MS Patients: A 7T-MRI Cohort Study Shuzhen Guan |
|
| -- |
ID 34: Using the VAP-S to assess executive disorders in patients with multiple sclerosis Romain Delsanti |
|
| -- |
ID 47: COVID-19 organising pneumonia in CNS inflammatory diseases treated with anti-CD20 Réné Carvajal |
|
| -- |
ID 60: From Seizures to Cognitive Decline: Unmasking Anti-CASPR2 Limbic Encephalitis Valentina Ciampana |